Moloney Securities Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$4.47M Sell
5,854
-203
-3% -$151K 0.53% 42
2025
Q2
$4.72M Sell
6,057
-820
-12% -$637K 0.58% 32
2025
Q1
$5.68M Buy
6,877
+388
+6% +$323K 0.77% 23
2024
Q4
$5.01M Sell
6,489
-51
-0.8% -$42.2K 0.67% 36
2024
Q3
$5.79M Buy
6,540
+1,178
+22% +$1.06M 0.78% 27
2024
Q2
$4.86M Buy
5,362
+78
+1% +$62.4K 0.7% 32
2024
Q1
$4.11M Buy
5,284
+91
+2% +$64.8K 0.62% 39
2023
Q4
$3.03M Sell
5,193
-40
-0.8% -$23.3K 0.48% 53
2023
Q3
$2.81M Sell
5,233
-38
-0.7% -$19.6K 0.51% 50
2023
Q2
$2.47M Buy
5,271
+1
+0% +$419 0.44% 59
2023
Q1
$1.81M Buy
5,270
+402
+8% +$136K 0.34% 74
2022
Q4
$1.78M Sell
4,868
-132
-3% -$46.8K 0.39% 74
2022
Q3
$1.62M Buy
5,000
+28
+0.6% +$8.87K 0.39% 66
2022
Q2
$1.61M Sell
4,972
-80
-2% -$24K 0.38% 75
2022
Q1
$1.45M Buy
5,052
+323
+7% +$83.1K 0.28% 101
2021
Q4
$1.31M Sell
4,729
-12,773
-73% -$3.24M 0.22% 112
2021
Q3
$4.04M Buy
17,502
+13,391
+326% +$3.31M 0.74% 32
2021
Q2
$944K Sell
4,111
-124
-3% -$24.9K 0.17% 154
2021
Q1
$791K Buy
4,235
+96
+2% +$18.8K 0.16% 156
2020
Q4
$699K Sell
4,139
-3,741
-47% -$559K 0.16% 160
2020
Q3
$1.17M Buy
7,880
+1,122
+17% +$174K 0.31% 90
2020
Q2
$1.11M Buy
6,758
+228
+3% +$35K 0.32% 92
2020
Q1
$906K Buy
6,530
+2,144
+49% +$295K 0.32% 96
2019
Q4
$576K Sell
4,386
-220
-5% -$25.5K 0.18% 149
2019
Q3
$515K Buy
4,606
+62
+1% +$6.9K 0.17% 149
2019
Q2
$503K Buy
4,544
+564
+14% +$66.4K 0.17% 151
2019
Q1
$516K Buy
3,980
+109
+3% +$13.3K 0.18% 150
2018
Q4
$448K Buy
3,871
+1,582
+69% +$177K 0.18% 150
2018
Q3
$246K Sell
2,289
-194
-8% -$19.4K 0.09% 239
2018
Q2
$212K Buy
+2,483
New +$204K 0.08% 260
2018
Q1
Sell
-2,452
Closed -$207K 306
2017
Q4
$207K Buy
2,452
+1
+0% +$85 0.09% 236
2017
Q3
$210K Buy
2,451
+1
+0% +$82 0.09% 243
2017
Q2
$202K Buy
2,450
+49
+2% +$4K 0.1% 228
2017
Q1
$202K Buy
+2,401
New +$192K 0.1% 219

Other funds holding LLY

Moloney Securities Asset Management's LLY Position: Q3 2025 in Review

Moloney Securities Asset Management reduced its Eli Lilly (LLY) stake by 3.4% in Q3 2025, selling an estimated $151K and leaving 5,854 shares worth $4.47M. The position accounts for 0.53% of the portfolio, ranked #42.

Moloney Securities Asset Management first reported a position in LLY in Q1 2017 and has held it in 34 quarters since. The position peaked at $5.79M in Q3 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.

  • Moloney Securities Asset Management held 5,854 shares of Eli Lilly worth $4.47M as of Q3 2025.
  • Moloney Securities Asset Management sold 203 Eli Lilly shares in Q3 2025, an estimated $151K.
  • Eli Lilly made up 0.53% of Moloney Securities Asset Management's portfolio in Q3 2025, its #42 holding.
  • Moloney Securities Asset Management first reported a position in Eli Lilly in Q1 2017 and has held it in 34 quarters since.
  • Moloney Securities Asset Management's Eli Lilly position peaked at $5.79M in Q3 2024.
  • 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.

Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.